GlassScriptPhysician profile
Kaitlyn Terrell
NPI 1841823770
$4,393.00
in general payments reported to CMS, 2019-2025
35 companies · $322 in 2025
The $322 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,082 · 2022: $877 · 2023: $1,629 · 2024: $483 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,265 · Food and Beverage: $1,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,264.74 |
| Food and Beverage | $1,169.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $1,559.93 | 2023-2025 | |
| Abbvie INC. | $614.98 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $261.21 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $233.88 | 2021-2022 | |
| Janssen Biotech, INC. | $216.86 | 2021-2022 | |
| Intuitive Surgical, INC. | $174.20 | 2024 | |
| Axsome Therapeutics, INC. | $101.68 | 2024-2025 | Sunosi |
| Pfizer INC. | $98.43 | 2022-2024 | |
| Gilead Sciences, INC. | $93.67 | 2021-2022 | |
| Celgene Corporation | $88.67 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $88.23 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.29 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $76.96 | 2021 | |
| Harmony Biosciences LLC | $75.83 | 2023-2024 | Wakix |
| Braintree Laboratories, INC. | $67.75 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $52.62 | 2023-2024 | Ajovy |
| Impel Pharmaceuticals INC. | $50.61 | 2023 | Trudhesa |
| Glaxosmithkline, LLC. | $48.65 | 2022 | |
| Ironwood Pharmaceuticals, INC | $45.57 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $40.26 | 2025 | Exparel |
| Becton, Dickinson and Company | $36.01 | 2025 | Hemosphere |
| Takeda Pharmaceuticals U.S.A., INC. | $30.21 | 2022 | |
| Medtronic, INC. | $30.05 | 2022-2024 | Unid_pass |
| Jazz Pharmaceuticals INC. | $29.87 | 2024 | |
| Intercept Pharmaceuticals, INC. | $27.42 | 2021-2022 | |
| Inspire Medical Systems, INC. | $23.66 | 2024 | Inspire |
| Zoll Respicardia, INC. | $21.01 | 2023 | Remede System |
| Baxter Healthcare | $20.65 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Midsouth Orthopedics INC. | $19.80 | 2024 | |
| Lilly USA, LLC | $17.39 | 2023 | Emgality |
| Stryker Corporation | $16.84 | 2025 | Adherus Autospray Dural Sealant |
| Biohaven Pharmaceutical Holding Company LTD. | $15.57 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.65 | 2023 | Seglentis |
| Idorsia Pharmaceuticals US INC | $13.36 | 2022 | |
| Spineology INC. | $9.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Terrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.